9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)
Smith, D.A., Conkling, P., Richards, D., Alemany, C., Boyd, T., Garbo, L., Wu, H., Wages, D., Bexon, A., Murphy, J.Volume:
7
Language:
english
Journal:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(09)71861-0
Date:
September, 2009
File:
PDF, 68 KB
english, 2009
File converter
More search results
More benefits 
